Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Assessment of clinical parameters associated with mutational status in metastatic malignant melanoma: a single-centre investigation of 141 patients.

The British journal of dermatology - 1 Apr 2013

Schlaak M, Bajah A, Podewski T, Kreuzberg N, von Bartenwerffer W, Wardelmann E, Merkelbach-Bruse S, Büttner R, Mauch C, Kurschat P

Abstract excerpt

BACKGROUND: Inhibitors of the mutated, constitutively activated BRAF protein have shown efficacy in the treatment of metastatic melanoma in clinical trials. Mutation analysis especially of the BRAF, NRAS and KIT genes is essential to identify patients suitable for targeted therapies and has been introduced into routine patient care. OBJECTIVES: To correlate mutational status with clinical parameters including...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Disease Progression
Share to DNA Mutational Analysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Kaplan-Meier Estimate

Share to Melanoma

Share to Proto-Oncogene Proteins B-raf

Share to Proto-Oncogene Proteins c-kit

Share to Skin Neoplasms

Share to Sunlight

Source

Identifiers

PMID: 23528057
DOI: 10.1111/bjd.12140

Genes

BRAF
KIT
NRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Assessment of clinical parameters associated with mutational status in metastatic malignant melanoma: a single-centre investigation of 141 patients.PMID 23528057Read ↗

Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma.Semantic proximity Read ↗

BRAF, NRAS and C-KIT Advanced Melanoma: Clinico-pathological Features, Targeted-Therapy Strategies and Survival.Semantic proximity Read ↗

The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort.Semantic proximity Read ↗

The Impact of BRAF Mutational Status on Survival in Melanoma Patients: Single Centre Experience.Semantic proximity Read ↗

Determinants of BRAF mutations in primary melanomas.Semantic proximity Read ↗

The molecular profile of metastatic melanoma in Australia.Semantic proximity Read ↗

Frequency and Clinicopathological Profile Associated with Braf Mutations in Patients with Advanced Melanoma in SpainSemantic proximity Read ↗

Prognostic and predictive values of oncogenic BRAF, NRAS, c-KIT and MITF in cutaneous and mucous melanoma.Semantic proximity Read ↗

Prevalence of BRAF, NRAS and c-KIT mutations in Slovenian patients with advanced melanoma.Semantic proximity Read ↗

Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.Semantic proximity Read ↗

Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma.Semantic proximity Read ↗

BRAF somatic mutations in malignant melanoma and melanocytic naevi.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.